评估肾小球滤过率下降治疗效应的临床试验设计
本文基于EMPA-REG Outcome(恩格列净vs安慰剂,含洗脱期)与SONAR(阿曲生坦vs安慰剂,含活性导入期后随机撤药)两项试验的事后分析,比较洗脱设计与活性导入随机撤药设计同标准随机设计计算的GFR下降疗效。两种设计中药物对GFR下降的效应与标准慢性斜率估计相近,且统计效能优于标准随机设计,作者认为这两种设计适合用于计算治疗对GFR下降的效应。
要点
- 恩格列净vs安慰剂对慢性GFR斜率的效应为1.72(95%CI 1.49-1.94)mL/min/1.73 m2/年,与洗脱期总下降估计1.64(1.44-1.85)相近。
- 阿曲生坦vs安慰剂对慢性GFR斜率的效应为0.72(0.32-1.11)mL/min/1.73 m2/年,与按治疗特异性基线估算的总斜率0.77(0.39-1.14)相近。
- 两种替代设计的统计效能均优于标准随机设计,作者认为洗脱设计与活性导入随机撤药设计是计算治疗对GFR下降效应的合适模型。
核心结论
- 洗脱设计与活性导入随机撤药设计是计算治疗对GFR下降效应的合适模型,其估计值与标准随机设计的慢性斜率相近,且统计效能优于标准随机设计。
研究设计与样本
- 对两项临床试验进行事后分析:EMPA-REG Outcome检验恩格列净vs安慰剂并含洗脱期,SONAR检验阿曲生坦vs安慰剂并含活性导入期后随机撤药。
- 将标准随机设计下从首次治疗访视至治疗结束计算的慢性GFR斜率,与从随机化至洗脱期结束的GFR变化、或从治疗特异性基线GFR值至治疗结束的GFR变化进行比较。
主要发现
- 恩格列净vs安慰剂对慢性GFR斜率的效应为1.72(95%CI 1.49-1.94)mL/min/1.73 m2/年,线性混合模型下从基线至洗脱期结束的总GFR下降为1.64(95%CI 1.44-1.85)mL/min/1.73 m2/年。
- 阿曲生坦vs安慰剂对慢性GFR斜率的效应为0.72(95%CI 0.32-1.11)mL/min/1.73 m2/年,按治疗特异性基线GFR值估算的单斜率模型总斜率为0.77(95%CI 0.39-1.14)mL/min/1.73 m2/年。
- 两种设计的统计效能均优于标准随机设计。
关键数值与推荐
- 恩格列净vs安慰剂慢性GFR斜率效应1.72(95%CI 1.49-1.94)mL/min/1.73 m2/年,对应洗脱期总下降1.64(95%CI 1.44-1.85)mL/min/1.73 m2/年。
- 阿曲生坦vs安慰剂慢性GFR斜率效应0.72(95%CI 0.32-1.11)mL/min/1.73 m2/年,对应治疗特异性基线估算的总斜率0.77(95%CI 0.39-1.14)mL/min/1.73 m2/年。
临床怎么用
- 作者认为洗脱设计与活性导入随机撤药设计是计算治疗对GFR下降效应的合适模型。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glomerular filtration rate (GFR) decline is used as surrogate endpoint for kidney failure. Interventions that reduce chronic kidney disease (CKD) progression often exert acute GFR reductions which differ from their long-term benefits and complicate the estimation of long-term benefit. Here, we assessed the utility of two alternative trial designs (wash-out design and active run-in randomized withdrawal design) that attempt to exclude the impact of acute effects. Post-hoc analyses of two clinical trials that characterized the effect of an intervention with acute reductions in GFR were conducted. The two trials included a wash-out period (EMPA-REG Outcome testing empagliflozin vs placebo) or an active run-in period with a randomized withdrawal (SONAR testing atrasentan vs placebo). We compared the drug effect on GFR decline calculated from the first on-treatment visit to the end of treatment (chronic slope in a standard randomized trial design) with GFR change calculated from randomization to end of wash out, or GFR change from treatment-specific baseline GFR values (GFR at start-of-run-in for placebo and end-of-run-in for atrasentan) until end-of-treatment. The effect of empagliflozin versus placebo on chronic GFR slope was 1.72 (95% confidence interval 1.49-1.94) mL/min/1.73 m2/year, similar to total GFR decline from baseline to the end of wash-out period using a linear mixed model 1.64 (1.44-1.85) mL/min/1.73 m2/year). The effect of atrasentan versus placebo on chronic GFR slope was 0.72 (0.32-1.11) mL/min/1.73 m2/year, similar to total slope from a single slope model when estimated from treatment specific baseline GFR values 0.77 (0.39-1.14) mL/min/1.73 m2/year). Statistical power of the two designs outperformed the standard randomized design. Thus, wash-out and active-run-in randomized-withdrawal trial designs are appropriate models to compute treatment effects on GFR decline.
引用
- Heerspink HJL, Little DJ, Frison L, et al. Clinical trial designs to assess treatment effects on glomerular filtration rate decline. Kidney Int. 2024. PMID: 38969296. doi:10.1016/j.kint.2024.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。